SEC Filings

SEC Filings

Filing date	Description	Form	View
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005737.pdf 0001214659-18-005737.rtf 0001214659-18-005737.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005738.pdf 0001214659-18-005738.rtf 0001214659-18-005738.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005739.pdf 0001214659-18-005739.rtf 0001214659-18-005739.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005740.pdf 0001214659-18-005740.rtf 0001214659-18-005740.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005741.pdf 0001214659-18-005741.rtf 0001214659-18-005741.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005742.pdf 0001214659-18-005742.rtf 0001214659-18-005742.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005743.pdf 0001214659-18-005743.rtf 0001214659-18-005743.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005744.pdf 0001214659-18-005744.rtf 0001214659-18-005744.xls
Aug 27, 2018	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-18-005745.pdf 0001214659-18-005745.rtf 0001214659-18-005745.xls
Aug 22, 2018	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	View HTML 0001104659-18-053209.pdf 0001104659-18-053209.rtf 0001104659-18-053209.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE